8-KEarnings & ResultsFinancial EventsExhibits & Filings

CARDINAL HEALTH INC 8-K Report, Financial Results (Sep 13, 2004)

Filed September 13, 2004For Securities:CAH

Summary

Cardinal Health Inc. (CAH) filed an 8-K on September 13, 2004, to announce significant accounting issues that necessitate the restatement of its financial statements for fiscal years 2001, 2002, and 2003, as well as the first three quarters of fiscal 2004. This action is a result of an ongoing SEC investigation and an internal review by the company's Audit Committee. The primary issues identified relate to the improper classification of sales within its Pharmaceutical Distribution segment, the undisclosed impact of accelerating cash discounts from suppliers, and various balance sheet reserve and accrual adjustments, including the accounting for vitamin manufacturer recoveries. Investors should be aware that the previously issued financial statements for the specified periods should no longer be relied upon. The company is cooperating with the SEC and the U.S. Attorney's office, and while it has identified certain restatements, there's a possibility of further issues emerging as the reviews continue. The full impact of these restatements, along with any additional findings, will be detailed in the upcoming Form 10-K for the fiscal year ended June 30, 2004. The company cannot predict the outcome of these investigations, which could lead to penalties or sanctions.

Key Highlights

  • 1Cardinal Health is restating financial statements for fiscal years 2001, 2002, 2003, and the first three quarters of fiscal 2004 due to accounting irregularities.
  • 2The restatements are driven by an ongoing SEC investigation and an internal Audit Committee review.
  • 3Key issues include improper classification of sales revenue (Operating Revenues vs. Bulk Deliveries) in the Pharmaceutical Distribution segment.
  • 4The company failed to adequately disclose the earnings impact of accelerating cash discounts from suppliers.
  • 5Balance sheet reserve and accrual adjustments, including vitamin manufacturer recoveries, also require restatement.
  • 6Previously issued financial statements for the affected periods should no longer be relied upon by investors.
  • 7The full impact of restatements and potential further issues will be disclosed in the upcoming Form 10-K.
  • 8The company faces ongoing investigations from the SEC and the U.S. Attorney's office, with uncertain outcomes that could involve penalties.

Frequently Asked Questions

This 8-K filing is primarily to inform investors that Cardinal Health's previously issued financial statements for fiscal years 2001, 2002, 2003, and the first three quarters of fiscal 2004 are unreliable and need to be restated. This is due to findings from an ongoing SEC investigation and an internal review by the company's Audit Committee.

The main issues involve: 1) Incorrectly classifying certain 'Bulk Deliveries' as 'Operating Revenues' within the Pharmaceutical Distribution segment. 2) Not adequately disclosing the financial impact of accelerating supplier payments to capture cash discounts. 3) Errors and inconsistencies related to balance sheet reserves, accruals, and accounting for recoveries from vitamin manufacturers.

The filing indicates that previously reported revenues and earnings for certain periods will be adjusted. While the improper classification of sales did not impact total revenues or net earnings, the acceleration of cash discounts did affect operating results, and various reserve adjustments will lead to restated net earnings for fiscal years 2002, 2003, and the year-to-date period of fiscal 2004. The full extent of the impact, including any further issues, will be detailed in the upcoming Form 10-K.

The company is subject to ongoing investigations by the SEC and the U.S. Attorney's office. The outcome of these investigations is uncertain and could result in administrative, civil, or criminal proceedings, including fines, penalties, and other sanctions.